Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

1,525 recalls · Class III, newest first

Class III · Low risk

Protonix I.V.

Subpotent Drug: Out of Specification (OOS) for potency at the 6-month stability time point.

Terminated Wrong potency / content Pfizer Inc. NDC 0008-0923-51 D-0516-2017
Class III · Low risk

Amoxicillin for Oral suspension

Labeling: Label Error on Declared Strength: Some bottles miss a color coded panel where the strength of the product is typically displayed.

Terminated Labeling / mix-up West-Ward Pharmaceuticals Corp. NDC 0143-9887-01 D-0147-2017
Class III · Low risk

Invokamet (canagliflozin and metformin HCl)

Labeling: Incorrect or Missing Package Insert - Xarelto prescribing information outserts may be affixed to the exterior of Invokamet bottles in place of the Invokamet prescribing information outsert.

Terminated Labeling / mix-up Janssen Ortho L.L.C. NDC 50458-543-60 D-0115-2017
Class III · Low risk

Zeasorb AF

Labeling Not Elsewhere Classified: front labels have the incorrect NDC or 0145-1506-01 instead of the correct NDC of 0145-1506-05 and some back labels have the incorrect indication stating "use for the cure of most jock itch" rather than "use for the cure of most athlete's foot".

Terminated Labeling / mix-up GSK Consumer Healthcare NDC 0145-1506-01 D-0142-2017
Class III · Low risk

Olanzapine tablets

Failed impurities/degradation specifications: due to out-of-specification result for the Related Substance Compound C (Impurity 6 - N-Oxide at the 18 month stability station.

Terminated Impurity / degradation Dr. Reddy's Laboratories, Inc. NDC 55111-163-30 D-0468-2017
Class III · Low risk

Paricalcitol Capsules

Failed Impurities/Degradation Specifications: This repackaged product was recalled by its manufacturer due to failed results for impurities.

Terminated Impurity / degradation Amerisource Health Services NDC 60687-106-25 D-0009-2017
Class III · Low risk

Clonazepam Tablets

Failed Impurities/Degradation Specifications: out of specification result for Clonazepam Related Compound (RC) A (a known impurity) at 16 month timepoint.

Terminated Impurity / degradation Mylan Institutional, Inc. (d.b.a. UDL Laboratories) NDC 51079-882-20 D-0136-2017

Recalls by year